Apoptotic and necrotic tumor cells release DNA into plasma, providing an accessible tumor biomarker. Tumor-released plasma-circulating DNA can be screened for tumor-specific genetic changes, including mutation, methylation, or allelic imbalance. However, technical problems relating to the quantity and quality of DNA collected from plasma hinder downstream genetic screening and reduce biomarker detection sensitivity. Here, we present a new methodology, blunt-end ligation-mediated whole genome amplification (BL-WGA), that efficiently amplifies small apoptotic fragments (<200 bp) as well as intermediate and large necrotic fragments (>5 kb) and enables reliable high-throughput analysis of plasma-circulating DNA. In a single-tube reaction, purified doublestranded DNA was blunted with T4 DNA polymerase, selfligated or cross-ligated with T4 DNA ligase and amplified via random primer-initiated multiple displacement amplification. Using plasma DNA from breast cancer patients and normal controls, we demonstrate that BL-WGA amplified the plasma-circulating genome by ϳ1000-fold. Of 25 informative polymorphic sites screened via polymerase chain reaction-denaturating high-performance liquid chromatography, 24 (95%) were correctly determined by BL-WGA to be allelic retention or imbalance compared to 44% by multiple displacement amplification. By enabling target magnification and application of high-throughput genome analysis, BL-WGA improves sensitivity for detection of circulating tumor-specific biomarkers from bodily fluids or for recovery of nucleic acids from suboptimally stored specimens
Solid malignant tumors release a significant amount of genomic DNA into the systemic circulation through cellular necrosis and apoptosis, [1] [2] [3] [4] [5] and this circulating DNA can be exploited as an accessible tumor-specific biomarker. [1] [2] [3] [5] [6] [7] Tumor-released DNA can be detected as a result of specific genetic changes, including mutations, methylation, translocation, presence of viral genes, or allelic imbalance (AI), a marker for potential deletion of tumor suppressor genes. [5] [6] [7] [8] [9] For example in breast cancer, tumor-released DNA in plasma provides a useful biomarker for breast cancer diagnosis and for monitoring relapse and metastasis. 10 -21 AI in particular is present in the majority of primary breast tumors and is also encountered in the plasma of breast cancer patients. [22] [23] [24] [25] [26] In the great majority of cases, AI in plasma corresponds to alterations in the primary tumor of the respective patient. 10, [12] [13] [14] 16 Plasma-circulating tumor DNA at diagnosis of breast cancer is a predictor of disease-free survival 19 and correlates with clinicopathological features and disease stage. 13 Although genetic alterations such as AI in plasmacirculating DNA have been shown to have clinical utility as biomarkers for early cancer detection or therapy monitoring, there are technical difficulties limiting their widespread application to cancer screening. Because of the genetic heterogeneity of tumors, no single biomarker is present in 100% of primary tumors. 6 Further, plasmacirculating DNA of tumor origin often contains only a fraction of the primary tumor alterations that may reflect the existence of different clones within the same tumor. 27, 28 In addition, plasma-circulating DNA may contain normal DNA, which complicates detection of tumorspecific genetic changes. 7, 29 To increase sensitivity and specificity of biomarker-based tumor detection, a panel of biomarkers and techniques must be used for each patient, 21 and there is a need for using high-throughput methodologies for detection of DNA alterations in plasma. 21 The amount of DNA circulating in the plasma of cancer patients is often low, with a median of ϳ59 ng of DNA per ml of blood. 7 Because low quantity of DNA template is a source of false-positives (allele dropout) and false-negatives (omission of AI), 30 -34 at least 5 ng of genomic DNA template is recommended per polymerase chain reaction (PCR). 30 Consequently, the number of genes that can be reliably examined for tumor-specific alterations via PCR-based methodologies is limited by the availability of starting material.
Whole genome amplification of plasma-circulating DNA could alleviate problems associated with low-input DNA. Whole genome amplification generates micrograms of DNA when starting from nanogram quantities of material and should enable high-throughput screening for a comprehensive study of genetic abnormalities in plasma-circulating DNA. However, reliable whole genome amplification presents a significant challenge because plasma-circulating DNA consists of a mixture of fragmented apoptotic and necrotic DNA ranging from low (100 to 200 bp) to high (Ͼ2 kb) sizes that are difficult to amplify uniformly. Ligation-mediated PCR methodologies 35, 36 can amplify fragmented DNA; 37 however, the genome coverage by PCR is incomplete because only a small fraction (a representation) of the original material is usually amplified. 38 Multiple displacement amplification (MDA) provides almost complete genome coverage 39, 40 but has a low efficiency when used with fragmented DNA, 41, 42 and thus the lower size DNA fragments of plasma-circulating DNA would not be represented.
Here we present a new adaptation of MDA developed specifically for efficient amplification of fragmented nucleic acids collected from plasma-circulating DNA or other bodily fluids. The new method utilizes two additional steps before random primer-initiated multiple displacement, ie, conversion of DNA fragments to blunt-ends by T4 DNA polymerase followed by self-ligation or crossligation via T4 DNA ligase ( Figure 1 ). The resulting large or circular DNA fragments are then amplified via randomprimer initiated MDA. We demonstrate that this blunt-end ligation-mediated whole genome amplification (BL-WGA) enables efficient, unbiased amplification of small (Ͻ200 bp), intermediate, and very large (Ͼ5 kb) size DNA fragments without production of artifacts in the detection of AI in plasma-circulating DNA. BL-WGA enables highthroughput analysis for sensitive detection, discovery, and evaluation of tumor-specific DNA biomarkers in the blood of cancer patients.
Materials and Methods

Collection and Extraction of DNA
Human male genomic DNA was obtained from Promega (Madison, WI). Blood samples (plasma, lymphocytes) were obtained from the Dana-Farber/Harvard Cancer Center SPORE Bank, 30 patients with stage II to IV breast cancer and 3 metastatic colon cancer patients, following informed consent and institutional review board approval from the Dana-Farber Cancer Institute. Blood samples were also obtained from 16 healthy individuals. Within 2 to 5 hours of collection, whole blood was centrifuged at 2000 ϫ g for 15 to 30 minutes, and plasma was carefully collected from the top of the supernatant. Plasma-circulating DNA was purified from plasma with QIAamp MinElute virus spin kit (Qiagen, Valencia, CA). Buffy coat was also removed for collection of genomic DNA from white blood cells. Normal and tumor breast tissue surgical specimens from 15 breast cancer patients were obtained from the Massachusetts General Hospital Tumor Bank. The QIAamp DNA mini kit (Qiagen) was used to purify genomic DNA from white blood cells and from normal and tumor tissues. DNA concentrations were measured by PicoGreen (Molecular Probes, Eugene, OR) as well as by a real-time PCR TaqMan assay performed as described. 37 
Blunt End Ligation-Mediated Whole Genome Amplification (BL-WGA)
A single tube whole genome amplification protocol was developed. Briefly, 2 to 4.5 l of plasma DNA (ϳ2 to 5 ng total)) was blunted with 0.3 U of T4 DNA polymerase (New England Biolabs, Beverly, MA) at 12°C for 15 minutes in 5 l of 1ϫ T4 DNA ligase buffer (New England Biolabs), supplemented with dNTP (Applied Biosystems, Foster City, CA) at a final concentration 100 mol/L. The T4 DNA polymerase was then heat-inactivated at 75°C for 20 minutes. The blunted DNA was ligated with 0.25 l of T4 DNA ligase (2000 U/l, New England Biolabs) in a volume of 5.25 l at room temperature for 2 hours. Ligase was heat-inactivated at 65°C for 10 minutes. The sample was then amplified using the GenomiPhi (Amersham Biosciences, Buckinghamshire, UK) whole genome amplification kit. Next, 9 l of random hexamer-containing buffer was added to 5.25 l of ligated DNA and heated at 95°C for 3 minutes to denature the template followed by rapid cooling on ice. The mixture of 9 l of reaction buffer plus 1 l of enzyme mix was added to the cooled sample. The reaction mixture was incubated at 30°C for 16 hours. Finally the reaction was stopped via heating at 65°C for 
MDA
For comparison to BL-WGA, MDA was performed in parallel on the plasma-circulating DNA samples using the GenomiPhi DNA amplification kit (Amersham Biosciences) per the company's specifications.
Evaluation of Whole Genome Amplification via TaqMan Real-Time PCR
Real-time PCR TaqMan assays were performed to determine the relative amplification of specific genes after whole genome amplification of plasma-circulating DNA. The assay was done as previously described. 37 Briefly, amplification was performed using AmpliTaq Gold (Applied Biosystems) in a smart-Cycler (Cepheid, Sunnyvale, CA). Primers and probes for exonic regions of genes studied were synthesized by Biosearch Technologies (Novato, CA). One l of amplified plasma-circulating DNA was added to a final volume of 20 l with a final concentration of 1ϫ ABI TaqMan master mix (Applied Biosciences), 0.2 mol/L each primer, and 0.1 mol/L probe. The thermocycling program was as follows: 1 cycle of 50°C for 2 minutes, 1 cycle of 95°C for 10 minutes, 50 cycles of 95°C for 15 seconds, 60°C for 1 minute. Three independent experiments were performed for each gene to generate an average relative copy number and SD. Alternatively, unamplified plasma-circulating DNA was diluted to the same final volume as the BL-WGA/MDA amplification reactions and tested via realtime PCR. The relative gene amplification between unamplified/amplified plasma-circulating DNA was calculated using the comparative threshold (⌬⌬C T ) method. 37, 43 
Dependence of Amplification on DNA Fragment Size
To estimate the amount of amplification performed by BL-WGA or MDA as a function of DNA fragment size, fragmentation of intact DNA was performed with restriction enzymes that yield predictable DNA fragment sizes ranging from 90 bp to 11,466 bp. DNA digested with restriction enzymes were run on 1% agarose gel to confirm the DNA smear and complete loss of the full-length genomic DNA band. After whole genome amplification, the amplification-fold of specific fragments was assessed via real-time PCR. Specifically, human male genomic DNA (ϳ1 g) was digested with TaqI, NlaIII, or DpnII (New England Biolabs) according to the manufacturer's instructions. Digested DNA was purified with the Qiagen PCR purification kit. DNA concentrations were measured via PicoGreen (Molecular Probes), and 10 ng of purified DNA was amplified via MDA or BL-WGA. An equal amount of DNA was also diluted in GenomiPhi sample/ reaction buffer in the absence of the enzyme mix to serve as unamplified control. Real-time TaqMan PCR was per-formed using unamplified DNA or whole genome-amplified DNA as described previously. 37 The amplificationfold for specific genes was calculated by obtaining the relative threshold difference (⌬⌬C T ) between amplified and unamplified samples.
Detection of AI and Microsatellite Changes via Denaturating High-Performance Liquid Chromatography (dHPLC)
The PCR-dHPLC method for detecting AI 44, 45 was used to screen amplified and unamplified plasma-circulating DNA at 23 polymorphic (single nucleotide polymorphisms [SNP]), positions described in Table 1 . PCR-dHPLC was performed as described. 42, 46 Briefly, PCR of unamplified or amplified plasma-circulating DNA, or genomic DNA from tissue or white blood cells, was performed using Advantage-HF-2 PCR kit (BD-Clontech Biosciences, Palo Alto, CA). We added 1 to 2 l of unamplified, or 1:10 diluted amplified plasma-circulating DNA (alternatively, 5 ng genomic DNA from lymphocytes) to a 10-l reaction with 1ϫ BD-Clonetech HF-2 PCR buffer, 1ϫ dNTP mix, forward and reverse primer each 0.4 mol/L, and 1ϫ BD Advantage-HF-2 polymerase mix. The PCR cycling was done in a Perkin-Elmer 9600 PCR machine (Perkin-Elmer, Emeryville, CA). Thermocycling conditions were as follows: 94°C for 1 minute (94°C for 20 seconds, 65°C for 20 seconds, 68°C for 1 minute) ϫ 10 cycles, with annealing temperature decreasing 1°C/cycle, touch-down PCR (94°C for 20 seconds, 55°C for 20 seconds, 68°C for 1 minute) ϫ 32 cycles, 68°C for 5 minutes, and 4°C hold. The PCR program was followed by heat-denaturation at 95°C for 2 minutes and slow (1°C/ minute) cooling to room temperature to generate heteroduplexes. PCR product (5 l) was injected into the WAVE dHPLC system (Transgenomic Inc., Omaha, NE) at the corresponding partially denaturing temperature for each PCR product, as described in Table 1 . The data were collected and analyzed using Navigator software and finally exported and plotted using Origin software (OrginLab Corp., Northampton, MA). Experiments were repeated at least three independent times, starting from unamplified plasma-circulating DNA each time.
In addition, the conventional PCR-dHPLC methodology for screening microsatellite changes in unamplified plasma-circulating DNA was performed. Six microsatellite markers, D17S855, D17S654, D16S421, TH 2 , D10S197, and D9S161, that often display AI in breast tumors and plasma-circulating DNA 13, 19, 20 were screened via PCR-dHPLC. Titanium Taq polymerase (BD-Clontech) was used in a 25-l PCR reaction volume with 10 ng of genomic DNA. PCR conditions were as follows: 94°C for 30 seconds (94°C for 20 seconds, 65°C for 20 seconds, 68°for 1 minute) ϫ 10 cycles with annealing temperature decreasing 1°C/cycle, touch-down PCR, 25 cycles (94°C for 20 seconds, 55°C for 20 seconds) ϫ 25 cycles, 68°C for 1 minute, and 4°C hold. PCR product (12 l) was introduced into the mobile phase by the dHPLC autosampler, and the sample was analyzed for microsatellite size changes at 50°C under nondenaturing conditions.
Results
dHPLC Screening of Microsatellite Imbalance in Unamplified Plasma-Circulating DNA
The conventional approach of screening microsatellites in genomic regions frequently presenting loss of heterozygosity in primary breast tumors and in plasma 13, 19, 20 was first applied in samples from five early stage (II/III) breast cancer patients. The PCR-dHPLC methodology 44, 45 was applied to screen six microsatellite markers for differences in plasma DNA versus the corresponding lymphocyte genomic DNA, as reported by Silva and colleagues. 13, 19, 20 The results demonstrated no microsatellite changes in plasma in any of these samples, except in one sample where microsatellite instability was detected for a single marker (Figure 2) . The 1-ml plasma sample available for this study did not allow examination of additional microsatellite markers to increase the probability for detecting AI in at least one marker. Dilution of the starting material was not considered due to the welldocumented allele-dropout artifacts associated with limited starting material in plasma-circulating DNA. 30 -34 Instead, whole genome amplification was applied to a portion of the remaining DNA, followed by AI screening at 23 SNP positions as described below.
Range of DNA Sizes Amplified via BL-WGA or MDA
We used a simplified system to study the DNA fragment size dependence of BL-WGA compared to MDA. Using three restriction enzymes to digest intact genomic DNA in separate reactions, distinct DNA fragment sizes ranging from 99 to 11,466 bp were predictably obtained, encom- passing a set of genes for which TaqMan real-time PCR probes were available. BL-WGA and MDA were performed in parallel for each restriction enzyme used and real-time PCR was used to quantify the amplification for each gene. Figure 3A demonstrates that MDA successfully amplified (Ͼ10 cycles difference, ie, Ͼ1000-fold) DNA fragments larger than 3 kb. For fragments ϳ1 kb, the MDA results were mixed, ie, MDA substantially amplified 1016-bp (HBEGF) and 1330-bp (RAN) fragments but failed to amplify fragments of 1272 bp (TFR), 1260 bp (HER2), and 1629 bp (E2F) ( Figure 3B ). As could be expected, MDA consistently did not amplify fragments below 1 kb ( Figure 3A) . In comparison, BL-WGA ampli-fied all tested DNA fragments with similar amplification efficiency, 2-to 4000-fold ( Figure 3C ). The data indicate that the method can potentially amplify equally apoptotic (Ͻ0.2 to 0.4 kb) and necrotic (Ͼ1 kb) DNA fragments from plasma-circulating DNA, resulting in a complete genome coverage similar to that produced when MDA is applied to intact genomic DNA. 40 
Real-Time PCR Evaluation of BL-WGA or MDA-Amplified Plasma-Circulating DNA
The TaqMan real-time PCR assay was used for an evaluation of amplification efficiency after amplification of plasma-circulating DNA via BL-WGA or MDA. For BL-WGA, representative growth curves obtained for three genes, HBEGF, CYC, and IL9R are depicted in Figure 4A . The difference in PCR threshold (C T ) between unamplified and BL-WGA amplified DNA is 10 to 12 cycles, which represents 1000-to 4000-fold amplification. A comparison of the efficiency of the two methods of amplification, BL-WGA and MDA, was then performed for nine genes using real-time PCR primers and probes previously described. 37 Results using plasma donated by seven individuals (two breast cancer patients, three colon cancer patients, and two normal volunteers) are depicted in Figure 4B . BL-WGA displays amplification of all nine genes examined in every sample tested. Specifically, BL-WGA generates an amplification of ϳ1000to 4000-fold in most genes examined, although one gene in sample p28 and two genes in p30 were only amplified by 50-to 100-fold. On the other hand, the MDA results are mixed, and amplification varies depending on the individual sample tested. In plasma sample p28 MDA did not amplify five of nine genes (IL9R, TBP, CD44, TGF-␤, and C-MYC) while MDA failed to amplify eight of nine genes in sample p30. For the three colon cancer samples and the two normal volunteers, MDA was able to generate a modest degree of amplification in several genes, although BL-WGA consistently produced higher amplification for the same genes. Statistically significant differences (P Ͻ 0.05, Student's t-test) between BL-WGA and MDA are demonstrated with an asterisk above each data point in Figure 4 . The data indicate that BL-WGA amplifies plasma-circulating DNA efficiently.
Evaluation of AI after Amplification of Plasma-Circulating DNA
The ability to faithfully amplify both alleles and avoid allele-dropout is one of the most exacting tests for a whole genome amplification method. 47 For a thorough evaluation of the fidelity of plasma-circulating DNA amplification, we examined the ability of BL-WGA to reproduce accurately the representation of both alleles, or to correctly diagnose AI in unamplified plasma, for a number of polymorphic (SNP) positions. PCR-dHPLC was used to discriminate between the two alleles in plasmacirculating DNA before and after amplification via BL-WGA or MDA. For each patient sample, matched 13, 19, 20 Other markers tested were negative for microsatellite changes in these patients (not shown). genomic DNA obtained from lymphocytes was used as a standard against which results from plasma were compared. Twenty-three SNPs were examined in samples obtained from a total of 30 breast cancer patients (stages II to IV) and 16 normal volunteers. Those SNPs that were informative in lymphocyte DNA obtained from the same patients were examined further using unamplified or amplified plasma-circulating DNA. The overall results for the informative SNPs, repeated three independent times, are summarized in Table 2 . The data demonstrate that MDA resulted in incorrect calls (allele dropout, amplification failure, or failure to identify AI) in 11 of 25 cases (44%), whereas BL-WGA generated incorrect calls in 1 of 25 cases (5%). Representative PCR-dHPLC chromatograms depicting correct and incorrect allele calls are shown in Figures 5 and 6 . Data in Figure 5 were obtained from three individuals for SNPs that were informative in the lymphocyte DNA (double peak in curve d). The dual peaks were also present in the unamplified and BL-WGAamplified plasma-circulating DNA (curve c and a) but converted to single peaks in the MDA-amplified plasmacirculating DNA (curve b) indicating allele dropout. Figure 6 demonstrates results from SNP S14 that demonstrated AI in unamplified plasma-circulating DNA (single peak, curve c) versus the corresponding lymphocyte DNA (double peak, curve d) in three patient samples. Correct detection of AI is seen in BL-WGA-amplified DNA (curve a, single peak) but only in one of three cases in MDA-amplified DNA (curve b).
In conclusion, although real-time PCR (Figure 4) indicates that MDA may amplify a substantial fraction of plasma-circulating DNA, the data in Table 2 and Figures  5 and 6 demonstrate that amplification is often incomplete and results in frequent amplification of only one of two alleles. This is in agreement to published reports. 47 On the other hand BL-WGA can reliably (95% accuracy) diagnose the zygosity of the sample after whole genome amplification of plasma-circulating DNA.
In the process of studying the amplification accuracy of BL-WGA, we identified AI of SNP S14 in the plasma of 3 of 10 informative breast cancer patients ( Table 2) but not in the plasma from 7 informative normal volunteers (zero of seven, data not shown). To evaluate if SNP S14 is also encountered in breast tumor tissue, we further screened 20 matched tumor/normal tissue surgical samples donated by patients with infiltrating ductal carcinoma. Nine of twenty samples were informative for SNP S14 and were screened for AI in the corresponding tumor DNA. Two of these nine samples presented AI in tumor tissue for SNP S14, while all matched normal samples demonstrated allelic retention. Figure 7 , A and B, depicts chromatograms from the two samples that demonstrated AI for S14 along with two samples that demonstrated allelic retention.
Discussion
In view of the reported limitations of MDA in amplifying fragmented DNA, such as DNA extracted from formalinfixed, paraffin-embedded specimens, we recently developed a rolling-circle amplification (RCA)-based whole genome amplification method, RCA-RCA. 42 RCA-RCA utilizes a restriction enzyme that digests DNA between successive formalin-induced damage sites and then circularizes the fragment via ligation, followed by rolling circle amplification. RCA-RCA generates a complete genomic amplification in formalin-fixed, paraffin-embedded samples of significant DNA degradation while retaining gene-dosage relations that are present before amplification. 42 However, a given DNA fragment must have at least two restriction sites to be amplified via RCA-RCA. Because plasma-circulating apoptotic DNA fragments are, for the most part, smaller than 200 bp, 2 it can be expected that a significant fraction of the apoptotic plasma-circulating DNA might not be amplified via RCA-RCA. The blunt-end ligation-mediated amplification described in the present study, BL-WGA, overcomes this problem because no restriction enzyme is required. By obviating the need for restriction sites, BL-WGA achieves efficient amplification of all DNA fragment sizes, including the apoptotic and necrotic DNA fractions that are present in plasma-circulating DNA. Reliable amplification of plasma-circulating DNA was not reported before. BL-WGA efficiently amplified both alleles of the studied genomic loci from plasma-circulating DNA whereas this was not the case for MDA (Figures 4 and 5 ). Quite possibly, AI AI F B. SNP S1, S7, S11, and S12 for patient 5
C. SNP S1, S2, S11, and S12 for patient 6 samples not amplified by MDA consisted mainly of apoptotic rather than necrotic DNA. By joining these small fragments together, BL-WGA generated DNA template amenable to efficient MDA and downstream analysis in these samples. The present study was aimed at validating reliability of AI detection after whole genome amplification, and therefore a direct comparison with PCR reactions performed from unamplified material was necessary to prove this point. Because the patient-donated plasma was limited (ϳ1 ml/sample), the study was restricted to examining 23 SNPs. However, it is evident that at least 1000-fold more SNPs could be examined for AI using the BL-WGA product, because the initial ϳ5 ng used for whole genome amplification yielded at least 5 g of DNA. Magnification of the examined target is expected to increase sensitivity in detecting AI or other genetic alterations in plasma-circulating DNA because numerous candidate genomic loci can be examined for alterations. 48 After examination of 23 polymorphic sites BL-WGA identified a SNP (db ϭ rs1395548, chromosome 1q23.3) that demonstrates AI in the plasma of 30% (3 of 10) of breast cancer cases examined but not in plasma from normal volunteers. AI in chromosome 1q of primary tumors has been reported 49 but was not confirmed in subsequent studies. 24 We therefore screened primary breast tumors from a separate set of patients and detected AI for SNP (db ϭ rs1395548) in ϳ22% (two of nine) of informative breast cancer cases but not their normal counterparts, suggesting that this chromosomal imbalance can be present in primary tumors as well as in the plasma of breast cancer patients.
Because matched tumor tissue from the patients donating the plasma was not available for a direct comparison, the present study confirms only the technical reliability of whole genome amplification from plasma-circulating DNA, ie, alterations detectable in the unamplified plasma are also present in the BL-WGA-amplified material. Several studies report that in the great majority of cases, plasma AI corresponds to AI in primary tumor. 10, [12] [13] [14] 16 Therefore, because AI detected in amplified plasma-circulating DNA corresponds faithfully to AI in unamplified plasma, it is likely that this reflects alterations in the primary tumor of the same patients. Further studies are warranted to validate this hypothesis.
In summary, we report on an improved whole genome amplification methodology, BL-WGA, which enables efficient amplification of both apoptotic and necrotic DNA fragments from plasma-circulating DNA and reliable downstream screening for AI or other genetic alterations. The method is simple to perform and enables highly expanded DNA screening that is expected to enhance overall sensitivity in detecting plasma DNA biomarkers. Further, BL-WGA generates adequate amplified material to enable use of microarrays that can examine the entire plasma-circulating genome and aid discovery of cancer fingerprints in plasma or identification of new cancer DNA biomarkers. BL-WGA is expected to have wide application in the comprehensive amplification of apoptotic/necrotic DNA collected from human fluid such as nipple aspirate, saliva, sputum, buccal swabs or dried blood specimens, or potentially in the recovery of suboptimally stored, degraded DNA samples. Plasma-Circulating DNA Screening in Plasma 29 JMD February 2006, Vol. 8, No. 1 
